Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04361682 | Preoperative Inflammatory Biomarkers and Postoperative Day 1 Drain Amylase Value Predict Pancreatic Fistula After Pancreaticoduodenectomy | completed | — | 227 | Campus Bio-Medico UniversityOTHER | 0 | Apr 24, 2020 | clinicaltrials |
| NCT01333124 | Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma | terminated | Phase 2 | 23 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 6, 2020 | clinicaltrials |
| NCT00454363 | Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2020 | clinicaltrials |
| NCT03172832 | A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors(INTERCPT) | terminated | N/A | 13 | Medical University of South CarolinaOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT02101918 | Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Mar 23, 2020 | clinicaltrials |
| NCT04058964 | Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 13, 2020 | clinicaltrials |
| NCT02681796 | Epidural Analgesia Use in Pancreatic Resections(E-PRO I) | completed | Phase 1 | 23 | Washington University School of MedicineOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT00948935 | Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma | completed | Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02456714 | Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma(4CC) | completed | Phase 2 | 30 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02635971 | Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer | unknown | Phase 2 | 168 | Fudan UniversityOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03949933 | Proton and Carbon Ion Radiotherapy for Locally Advanced Pancreatic Cancer | completed | N/A | 10 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Mar 5, 2020 | clinicaltrials |
| NCT01347333 | Stereotactic Body Radiotherapy for Liver Tumors | completed | N/A | 23 | Mercy ResearchOTHER | 1 | Mar 3, 2020 | clinicaltrials |
| NCT03277209 | To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas | terminated | Phase 1 | 2 | Weill Medical College of Cornell UniversityOTHER | 2 | Mar 2, 2020 | clinicaltrials |
| NCT03554434 | An Expanded Access Program for AM0010 (Pegilodecakin) | no longer available | — | — | Eli Lilly and CompanyINDUSTRY | 0 | Mar 2, 2020 | clinicaltrials |
| NCT03840460 | A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers(PaC-MAn) | unknown | — | 200 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 20, 2020 | clinicaltrials |
| NCT04269369 | Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients | unknown | Phase 4 | 250 | Jessa HospitalOTHER | 0 | Feb 13, 2020 | clinicaltrials |
| NCT00779454 | Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma | completed | Phase 2 | 72 | Vejle HospitalOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT03267966 | Margin Status After Pancreaticoduodenectomy for Cancer | completed | N/A | 168 | Campus Bio-Medico UniversityOTHER | 0 | Feb 6, 2020 | clinicaltrials |
| NCT04134468 | MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 31, 2020 | clinicaltrials |
| NCT01926236 | Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers(ABC06) | completed | Phase 3 | 162 | The Christie NHS Foundation TrustOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT02743975 | Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma(PENGUIN) | terminated | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Jan 28, 2020 | clinicaltrials |
| NCT03865563 | Selective Transvenous Chemoembolization of Primary Pancreatic Tumors | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04243057 | Diagnosis, Treatment Status and Prognosis of Cholangiocarcinoma in China: a Multicenter, Two-way, Non-intervention Study | unknown | — | 5,000 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT01431794 | Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 23 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03307148 | Stromal TARgeting for PAncreatic Cancer (STAR_PAC)(STAR_PAC) | completed | Phase 1 | 29 | Barts & The London NHS TrustOTHER | 1 | Jan 22, 2020 | clinicaltrials |
| NCT02496741 | Metformin And Chloroquine in IDH1/2-mutated Solid Tumors(MACIST) | completed | Phase 1 / Phase 2 | 15 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jan 9, 2020 | clinicaltrials |
| NCT03544255 | Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues | unknown | — | 50 | Ying LvOTHER | 1 | Jan 7, 2020 | clinicaltrials |
| NCT03811652 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 8 | MedImmune LLCINDUSTRY | 2 | Dec 30, 2019 | clinicaltrials |
| NCT02730611 | Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma(METSLIVER) | completed | — | 124 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT03578445 | Utility of EUS-guided Microbiopsies in Pancreatic Cystic Lesions | completed | N/A | 101 | Herlev HospitalOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT04189393 | Microbiome Analysis in esoPhageal, PancreatIc and Colorectal CaNcer Patients Undergoing Gastrointestinal Surgery(MA-PPING) | unknown | — | 60 | Radboud University Medical CenterOTHER | 0 | Dec 6, 2019 | clinicaltrials |
| NCT03771846 | HAIC Versus Systemic Chemotherapy for Unresectable ICC | unknown | Phase 3 | 188 | Shi MingOTHER | 1 | Dec 5, 2019 | clinicaltrials |
| NCT00728000 | Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | University of CincinnatiOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02749136 | Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer | completed | Phase 2 | 44 | Asan Medical CenterOTHER | 1 | Nov 25, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT02592538 | Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma | completed | N/A | 66 | First People's Hospital of HangzhouOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT03774589 | Bilioenteric Anastomosis by Magnetic Compressive Technique(BAMCT) | unknown | N/A | 200 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT03792048 | Magnetic Compressive Anastomosis for Biliojejunostomy and Pancreaticojejunostomy During Whipple's Procedure | unknown | N/A | 50 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Nov 18, 2019 | clinicaltrials |
| NCT04164992 | Endoscopic Ultrasound Radiofrequency Ablation (EUS-RFA) of Not-resectable Pancreatic Cancer | unknown | N/A | 15 | Campus Bio-Medico UniversityOTHER | 0 | Nov 18, 2019 | clinicaltrials |
| NCT03211169 | Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures | terminated | N/A | 12 | Stanford UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT04156958 | Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma(FSTAMBTA) | unknown | Phase 2 | 33 | Sichuan UniversityOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01413087 | Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma(LAPC-BC-819) | terminated | Phase 2 | 12 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Nov 1, 2019 | clinicaltrials |
| NCT00416793 | Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | terminated | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2019 | clinicaltrials |
| NCT01900158 | A Phase I/II Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas | completed | Phase 1 | 24 | PCI Biotech ASINDUSTRY | 4 | Oct 29, 2019 | clinicaltrials |
| NCT02620800 | Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer(FABLOx) | completed | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Oct 22, 2019 | clinicaltrials |
| NCT04130399 | Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Oct 17, 2019 | clinicaltrials |
| NCT03210298 | International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)(PIPACRegis) | unknown | — | 1,000 | Sabine RhodeOTHER | 13 | Oct 8, 2019 | clinicaltrials |
| NCT02926183 | Study of NAC of GA Therapy for Patients With BRPC | unknown | Phase 2 | 60 | Wakayama Medical UniversityOTHER | 1 | Oct 3, 2019 | clinicaltrials |
Data updated 24 days agoSource updated Apr 24, 2020source: clinicaltrials